Evidence map›Paper›PMID 37859722›Full record

ArticleRSC medicinal chemistry2023

Screening and optimization of phage display cyclic peptides against the WDR5 WBM site.

Lingyu Song, Jiawen Cao, Lin Chen, Zhiyan Du, Naixia Zhang, Danyan Cao, Bing Xiong

Open access · bronzeAbstract read
In one paragraph

Article in RSC medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lingyu SongDepartment of College of Pharmacy, University of Chinese Academy of Sciences 19A Yuquan Road Beijing 100049 China.
Jiawen CaoDepartment of College of Pharmacy, University of Chinese Academy of Sciences 19A Yuquan Road Beijing 100049 China.
Lin ChenDepartment of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences 555 Zuchongzhi Road Shanghai 201203 China s20-songlingyu@simm.ac.cn caody@simm.ac.cn bxiong@simm.ac.cn.
Zhiyan DuDepartment of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences 555 Zuchongzhi Road Shanghai 201203 China s20-songlingyu@simm.ac.cn caody@simm.ac.cn bxiong@simm.ac.cn.
Naixia ZhangDepartment of College of Pharmacy, University of Chinese Academy of Sciences 19A Yuquan Road Beijing 100049 China.
Danyan CaoDepartment of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences 555 Zuchongzhi Road Shanghai 201203 China s20-songlingyu@simm.ac.cn caody@simm.ac.cn bxiong@simm.ac.cn.
Bing XiongDepartment of College of Pharmacy, University of Chinese Academy of Sciences 19A Yuquan Road Beijing 100049 China.ORCID https://orcid.org/0000-0001-9776-8136
Chinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Of the various WD40 family proteins, WDR5 is a particularly important multifunctional adaptor protein that can bind to several protein complexes to regulate gene activation, so it was considered as a promising epigenetic target in anti-cancer drug development. Despite many inhibitors having been discovered directing against the arginine-binding cavity in WDR5 called the WIN site, the side hydrophobic cavity called the WBM site receives rather scant attention. Herein, we aim to obtain novel WBM-targeted peptidic inhibitors with high potency and selectivity. We employed two improved biopanning approaches with a disulfide-constrained cyclic peptide phage library containing 7 randomized residues and identified several peptides with micromole binding activity by docking and binding assay. To further optimize the stability and activity, 9 thiol-reactive chemical linkers were utilized in the cyclization of the candidate peptide DH226027, which had good binding affinity. This study provides an effective method to discover potent peptides targeting protein-protein interactions and highlights a broader perspective of peptide-mimic drugs.

Identifiers

PMID37859722
PMCPMC10583817
OpenAlexW4385949770

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.